Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Medicine, Therapy, Cancer |
389B | 62.3% | 81.4% | 78.7% | 105 | -0.25% |
| AMGN Amgen |
Biotechnology
Arthritis, Psoriasis |
152B | 79.9% | 69.2% | 32.4% | 23.1 | -28.0% |
| GILD Gilead Sciences |
Biotechnology
HIV,AIDS,Hepatitis,COVID,Cancer |
146B | 75.9% | 64.1% | 92.7% | 23.4 | 17.4% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Sickle Cell, Beta |
99.6B | 84.3% | - | 24.9% | 27.6 | -32.1% |
| ALNY Alnylam |
Biotechnology
Therapeutics, RNA Interference |
61.5B | 34.1% | - | 78.2% | - | 38.9% |
| REGN Regeneron |
Biotechnology
Injection, Antibody, Treatment |
59.2B | 78.5% | 1.0% | -40.6% | 14.3 | -56.7% |
| ARGX argenx |
Biotechnology
Therapies, Treatments |
47.0B | 82.2% | - | 73.7% | 38.8 | 18.6% |
| HLN Haleon |
Biotechnology
OralHealth, Vitamins, PainRelief |
44.2B | 55.0% | 44.9% | 53.3% | 21.9 | -24.2% |
| ONC BeiGene |
Biotechnology
Cancer Treatments, Oncology |
40.3B | 50.0% | - | 59.2% | - | 41.9% |
| INSM Insmed |
Biotechnology
Therapies, Treatments |
30.1B | 33.5% | - | 74.9% | - | 66.7% |
| 22UA BioNTech SE |
Biotechnology
Immunotherapies, Cancer |
24.2B | 32.7% | 1.0% | -59.8% | - | -36.8% |
| BNTX BioNTech SE |
Biotechnology
Immunotherapies, Cancer |
23.3B | 20.3% | 1.0% | -44.3% | - | -33.6% |
| NTRA Natera |
Biotechnology
Prenatal Tests, Genetic Screening |
23.0B | 47.5% | - | 65.4% | - | 16.4% |
| BIIB Biogen |
Biotechnology
Therapies, Multiple Sclerosis |
20.9B | 62.4% | - | -60.2% | 13.7 | -38.3% |
| SMMT Summit Therapeutics |
Biotechnology
Immunotherapy, Antibody, Cancer |
19.3B | 33.6% | - | 53.0% | - | -41.8% |
| UTHR United Therapeutics |
Biotechnology
Inhaled Solution, Injection |
17.9B | 90.7% | - | 43.6% | 15.5 | -1.29% |
| INCY Incyte |
Biotechnology
Cancer Treatments, Blood |
17.0B | 68.9% | - | 8.53% | 20.6 | 7.70% |
| GMAB Genmab AS |
Biotechnology
Antibody, Cancer, Lymphoma |
16.7B | 87.2% | - | -22.5% | 14.0 | -10.4% |
| BIM Biomerieux |
Biotechnology
Culture, PCR, AST, Sepsis, Software |
16.0B | 80.6% | 55.5% | 62.1% | 36.3 | -10.2% |
| NBIX Neurocrine |
Biotechnology
Pharmaceuticals, Neurology |
14.2B | 80.4% | - | 45.1% | 42.6 | -1.55% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
13.4B | 70.2% | 7.83% | 19.3% | 28.1 | 1.41% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone Therapy |
12.3B | 32.2% | - | 67.9% | - | 14.9% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
10.5B | 93.7% | - | 84.9% | 18.9 | 23.6% |
| BMRN Biomarin |
Biotechnology
Enzyme Replacement, Growth |
10.4B | 81.9% | - | -58.3% | 16.0 | -35.0% |
| IONS Ionis |
Biotechnology
Triglyceride,Neuromuscular,ADS,ATTR.. |
10.2B | 36.7% | 0.21% | 30.0% | - | 24.3% |
| BBIO BridgeBio Pharma |
Biotechnology
Attruby, Infigratinib, Encaleret |
10.1B | 45.5% | - | 74.3% | - | 61.5% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, MASH, Thyroid, Agonist |
9.52B | 30.7% | - | 77.0% | - | 50.9% |
| EXAS EXACT Sciences |
Biotechnology
Colon, Breast, Biomarker, Tumor |
9.33B | 45.8% | - | -20.2% | - | -35.0% |
| MRNA Moderna |
Biotechnology
Vaccines, Therapeutics, RNA |
9.15B | 18.6% | - | -85.9% | - | -70.7% |
| HALO Halozyme |
Biotechnology
Hyaluronidase Enzyme, Hylenex |
9.07B | 85.2% | - | 61.6% | 17.7 | 3.28% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin, Clotting |
8.69B | 64.7% | 29.3% | 9.92% | 19.0 | -6.04% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Inhibitor, Activator |
8.46B | 25.5% | - | 59.9% | - | 6.98% |
| RVMD Revolution |
Biotechnology
Targeted Therapies, RAS |
7.39B | 20.8% | - | 20.3% | - | -15.6% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, BCMA, Gamma-Delta |
6.66B | 32.9% | - | -25.4% | - | -43.2% |
| ABVX Abivax |
Biotechnology
Drug, Phase3, Ulcerative, Crohns |
6.63B | 42.6% | - | 38.3% | - | 466% |
| RGC Regencell |
Biotechnology
TCM,Neurocognitive,ADHD,Autism,Herb.. |
6.56B | 28.7% | - | 70.2% | - | 7,147% |
| ABVX Abivax American |
Biotechnology
Hepatitis,HIV,Autoimmune,Infection |
6.53B | 39.5% | - | 43.8% | - | 502% |
| RYTM Rhythm |
Biotechnology
IMCIVREE, Obesity-Drug |
6.50B | 42.3% | - | 88.6% | - | 52.5% |
| AAPG Ascentage Pharma |
Biotechnology
Cancer Drugs, Hepatitis Therapy |
6.35B | 23.2% | - | 96.6% | - | 105% |
| RNA Avidity Biosciences |
Biotechnology
Antibody, Oligonucleotide |
6.12B | 25.6% | - | 30.8% | - | -19.9% |
| CYTK Cytokinetics |
Biotechnology
Omecamtiv, Aficamten, CK089, CK586 |
5.98B | 45.3% | - | -20.7% | - | -28.6% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
5.74B | 23.3% | - | 31.8% | - | -36.7% |
| CRSP Crispr Therapeutics |
Biotechnology
Beta Thalassemia Therapy, Sickle |
5.12B | 27.6% | - | -15.6% | - | -0.07% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, TG-1701 |
5.10B | 60.4% | - | 60.5% | 84.6 | 7.78% |
| MRUS Merus BV |
Biotechnology
Bispecific,Antibodies,Cancer,Clinic.. |
5.08B | 28.2% | - | 77.2% | - | 14.8% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.95B | 89.2% | - | 23.6% | 14.5 | -15.2% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
4.61B | 84.8% | - | 33.8% | 7.88 | 45.9% |
| KRYS Krystal Biotech |
Biotechnology
VYJUVEK, Gene Therapies |
4.16B | 90.5% | - | 27.4% | 29.3 | -31.3% |
| MTSR Metsera, Common |
Biotechnology
Injectable, Oral, Peptides |
4.12B | 38.4% | - | 80.7% | - | 66.5% |
| PCVX Vaxcyte |
Biotechnology
Pneumonia Vaccine, Strep Vaccine |
4.10B | 17.7% | - | -11.6% | - | -77.7% |
| ADMA ADMA Biologics |
Biotechnology
Immune Globulin, Hepatitis B |
4.03B | 85.9% | - | 52.7% | 19.9 | -29.8% |
| ACAD ACADIA |
Biotechnology
Pimavanserin, Trofinetide |
3.98B | 62.0% | - | 41.4% | 17.8 | 25.6% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene, ACLX-001 |
3.95B | 33.2% | - | 42.4% | - | -17.3% |
| ARWR Arrowhead |
Biotechnology
Arrowhead, siRNA, Therapy, Liver |
3.87B | 26.7% | - | -23.4% | - | 22.8% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.82B | 43.8% | - | 90.8% | - | 53.2% |
| ZLAB Zai Lab |
Biotechnology
Zejula,Vyvgart,NUZYRA,Optune,Qinloc.. |
3.73B | 29.6% | - | 2.89% | - | 32.3% |
| PTGX Protagonist |
Biotechnology
Inject, Hepcidin, Mimetic |
3.66B | 70.2% | - | 75.5% | 80.6 | 11.3% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Prader-Willi |
3.57B | 33.1% | - | 69.5% | - | -18.7% |
| AKRO Akero Therapeutics |
Biotechnology
Efruxifermin, EFX, MASH Treatment |
3.52B | 22.7% | - | 60.0% | - | 33.6% |
| MLTX MoonLake |
Biotechnology
Sonelokimab, Tri-Specific |
3.38B | 26.4% | - | 54.3% | - | -15.3% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4 Program,STAT6 Program,TYK2 |
3.36B | 24.6% | - | 19.3% | - | -14.2% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
3.26B | 18.7% | - | 14.3% | - | -45.6% |
| LGND Ligand |
Biotechnology
Antiviral,Oncology,Vaccine,Respirat.. |
3.25B | 52.3% | 0.14% | 73.4% | - | 33.9% |
| SRRK Scholar Rock |
Biotechnology
Myostatin-Blocking Drug, Cancer |
3.18B | 26.9% | - | 48.1% | - | 227% |
| APLS Apellis |
Biotechnology
Empaveli, Syfovre, Geographical |
3.14B | 39.4% | - | -66.9% | - | -45.1% |
| XENE Xenon |
Biotechnology
Seizure Drugs, Pain Drugs |
3.02B | 32.0% | - | -12.1% | - | -22.8% |
| VKTX Viking Therapeutics |
Biotechnology
Drugs, Liver, Diabetes, Obesity |
3.02B | 19.3% | - | 23.4% | - | -69.1% |
| INDV Indivior Ordinary |
Biotechnology
Injection, Film, Tablet, Spray |
2.98B | 80.9% | 2.63% | 51.4% | 29.5 | 104% |
| RARE Ultragenyx |
Biotechnology
Antibody,Biologic,Gene,Enzyme,Oligo |
2.84B | 37.8% | - | -78.1% | - | -58.6% |
| NAMS NewAmsterdam |
Biotechnology
Cholesterol, Lowering, Medicine |
2.80B | 32.0% | - | 66.5% | - | 33.7% |
| MLYS Mineralys |
Biotechnology
Hypertension, Mineralocorticoid |
2.79B | 29.1% | - | 58.8% | - | 163% |
| KNSA Kiniksa |
Biotechnology
Arcaxya, Mavripaxa, Sub):) |
2.73B | 61.3% | - | 79.8% | 737 | 17.7% |
| IBRX Immunitybio |
Biotechnology
Vaccine Cancer, Cell Therapy |
2.66B | 49.2% | - | -65.9% | - | -29.9% |
| BIOA-B BioArctic (publ) |
Biotechnology
Biological Drugs, Antibodies |
2.63B | 52.7% | 0.21% | 72.4% | 22.5 | 37.5% |
| IMVT Immunovant |
Biotechnology
Antibody, Graves, Arthritis |
2.63B | 21.8% | - | 4.56% | - | -56.2% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Eye, Bone |
2.53B | 54.7% | - | -26.2% | 35.3 | -39.2% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.51B | 93.3% | - | 43.1% | 12.5 | -17.4% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
2.44B | 24.8% | - | 52.6% | - | 208% |
| TVTX Travere |
Biotechnology
Kidney Drug, Rare Disease Therapy |
2.43B | 30.8% | - | -4.42% | - | 38.6% |
| CNTA Centessa |
Biotechnology
Serpin, OXER1, Vasopressin |
2.42B | 31.3% | - | 53.1% | - | 13.2% |
| VCYT Veracyte |
Biotechnology
Cancer Biopsy Tests, Molecular |
2.41B | 61.5% | - | -0.78% | 90.1 | -21.8% |
| CGON CG Oncology |
Biotechnology
Cancer Immunotherapy Virus |
2.36B | 24.9% | - | -34.5% | - | -15.7% |
| FOLD Amicus Therapeutics |
Biotechnology
Enzyme,Replacement,Therapy,Gaucher,.. |
2.35B | 45.0% | - | -55.8% | - | -40.0% |
| BEAM Beam Therapeutics |
Biotechnology
Base Editing Platform |
2.32B | 22.8% | - | -72.3% | - | -26.0% |
| NNNN Anbio |
Biotechnology
Test, Kits, Devices, Reagents |
2.32B | 72.5% | - | 93.8% | 858 | 589% |
| APGE Apogee |
Biotechnology
Cystic Fibrosis,’Atopic |
2.26B | 29.1% | - | 14.7% | - | -37.3% |
| DNLI Denali Therapeutics |
Biotechnology
Alzheimer, Parkinson, ALS |
2.26B | 13.4% | - | -84.6% | - | -64.1% |
| BONEX Bonesupport Holding |
Biotechnology
Injectable Bio-Ceramic, Bone |
2.18B | 85.9% | - | 38.6% | 137 | -21.6% |
| IDYA Ideaya Biosciences |
Biotechnology
Cancer Drugs, Oncology Therapies |
2.17B | 16.6% | - | 18.8% | - | -42.4% |
| BLTE Belite Bio |
Biotechnology
Eye Drug, Eye Gene Therapy, Vision |
2.16B | 20.8% | - | 64.5% | - | 26.9% |
| GLPG Galapagos |
Biotechnology
Filgotinib, Jyseleca, Crohns |
2.15B | 39.9% | - | -43.2% | - | -17.7% |
| IRON Disc Medicine |
Biotechnology
Red, Blood, Iron, Drug, Clinical |
2.14B | 16.7% | - | 13.5% | - | 8.75% |
| RXRX Recursion |
Biotechnology
Drug,Candidates,Pipeline |
2.11B | 23.0% | - | -73.0% | - | -41.2% |
| GLPG Galapagos |
Biotechnology
Rheumatoid, Arthritis, Psoriatic |
2.08B | 26.2% | - | -25.1% | - | -10.9% |
| AGIO Agios Pharm |
Biotechnology
Pyruvate Kinase Activator, IDH |
2.07B | 36.7% | - | -11.8% | 3.16 | -32.8% |
| VITR Vitrolife |
Biotechnology
Media, Pipettes, Lasers, Dishes |
1.97B | 53.7% | 41.2% | -73.8% | 40.4 | -54.9% |
| SRPT Sarepta |
Biotechnology
Gene Therapy, Antisense, Duchenne |
1.90B | 40.2% | - | -74.2% | - | -88.6% |
| DYN Dyne Therapeutics |
Biotechnology
Muscle, Oligonucleotide, Therapy |
1.87B | 24.2% | - | -34.8% | - | -67.9% |
| MESO Mesoblast |
Biotechnology
Stem Cell Therapy, Regenerative |
1.86B | 27.9% | - | 47.7% | - | 108% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Seborrheic |
1.84B | 32.2% | - | 13.7% | - | 39.5% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Regenerative Medicine |
1.81B | 39.9% | - | -42.6% | - | -10.7% |
| IMCR Immunocore Holdings |
Biotechnology
Cancer Therapy, ImmTac, Melanoma |
1.78B | 47.3% | - | -6.54% | - | -16.8% |
| VIMIAN Vimian |
Biotechnology
Diagnostics, Pharma, Veterinary |
1.77B | 58.9% | - | -30.6% | 71.3 | -40.8% |
| MNKD MannKind |
Biotechnology
Inhaled,Insulin,Diabetes,Respirator.. |
1.76B | 76.8% | - | 3.87% | 52.2 | -30.7% |
| COGT Cogent Biosciences |
Biotechnology
Kit, Bemarituzumab |
1.75B | 40.6% | - | -3.54% | - | -0.88% |
| VCEL Vericel Ord |
Biotechnology
Cartilage Repair, Burn Wound, Cell |
1.69B | 60.1% | - | -13.1% | 240 | -42.9% |
| AUPH Aurinia |
Biotechnology
Kidney Transplant Drug |
1.68B | 85.8% | - | 36.2% | 29.7 | 45.3% |
| BCRX BioCryst |
Biotechnology
Oral Pill,Hereditary |
1.66B | 71.1% | - | -16.0% | - | -18.0% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
1.64B | 15.0% | - | 63.5% | - | 370% |
| ARDX Ardelyx |
Biotechnology
Kidney Drug, Bowel Drug |
1.60B | 30.6% | - | 33.7% | - | -15.1% |
| VERA Vera Therapeutics |
Biotechnology
Kidney, Antibody, Protein, Disease |
1.58B | 19.0% | 3.50% | -20.0% | - | -48.3% |
| VRDN Viridian |
Biotechnology
Antibody, Eye, Disease, Drug |
1.56B | 23.8% | - | -26.9% | - | -25.8% |
| EWTX Edgewise |
Biotechnology
Muscle, Disease, Drugs, Pipeline |
1.54B | 24.8% | - | -8.61% | - | -35.2% |
| TWST Twist Bioscience |
Biotechnology
Synthetic Dna,Gene,Silicon Chips |
1.53B | 32.5% | - | -59.7% | - | -52.3% |
| CLDX Celldex |
Biotechnology
Antibody, Vaccine, Cancer |
1.51B | 24.5% | - | -36.1% | - | -50.0% |
| BHVN Biohaven |
Biotechnology
Migraine Medicine, Neurology Drug |
1.49B | 38.0% | - | -3.69% | - | -68.2% |
| PGEN Precigen |
Biotechnology
UltraCAR-T, AdenoVerse, PRGN-3005 |
1.42B | 33.2% | - | 43.6% | - | 223% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin,Receptor,Antagonist,Drug.. |
1.40B | 25.2% | - | 37.8% | - | 0.32% |
| JANX Janux Therapeutics |
Biotechnology
T-Cell Redirectors, Prodrug Masks |
1.38B | 23.0% | - | -3.31% | - | -60.0% |
| GRAL GRAIL |
Biotechnology
Diagnostic, Screening, Cancer |
1.38B | 35.2% | - | 89.9% | - | 130% |
| ETNB 89bio |
Biotechnology
Experimental Therapy, Liver |
1.37B | 22.7% | - | 15.9% | - | -18.4% |
| SNDX Syndax |
Biotechnology
Antibody, Kinase, Inhibitor |
1.34B | 27.4% | - | -52.8% | - | -31.1% |
| NTLA Intellia |
Biotechnology
CRISPR, Gene, Editing |
1.26B | 29.2% | - | -76.6% | - | -53.6% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Discovery, Therapeutics |
1.21B | 17.5% | - | -24.7% | - | 41.2% |
| CVAC CureVac |
Biotechnology
mRNA Vaccines, mRNA Therapies |
1.21B | 84.9% | - | -6.26% | 5.33 | 37.9% |
| STOK Stoke Therapeutics |
Biotechnology
STK-002,Zorevunersen,ASOs,TANGO,Gen.. |
1.20B | 82.1% | - | 15.4% | 25.3 | 26.9% |
| NVAX Novavax |
Biotechnology
Vaccine, Covid, Nanoparticle |
1.20B | 57.5% | - | -75.3% | 3.33 | -45.3% |
| DVAX Dynavax |
Biotechnology
Vaccine, Infectious Diseases |
1.19B | 39.9% | - | -18.9% | - | -28.3% |
| LENZ LENZ Therapeutics |
Biotechnology
Presbyopia, Accommodative |
1.16B | 33.9% | 1.0% | 51.6% | - | 68.9% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immuno-Oncology |
1.15B | 23.7% | - | -74.8% | - | -39.3% |
| GPCR Structure |
Biotechnology
Small,Molecule,Drug,Candidates,Obes.. |
1.14B | 29.5% | - | -23.4% | - | -52.5% |
| OPK Opko Health |
Biotechnology
Diagnostics, Pharmaceuticals |
1.14B | 16.6% | - | -56.0% | - | -29.4% |
| BIOG-B BioGaia (publ) |
Biotechnology
Drops, Solutions, Tablets |
1.12B | 75.7% | 60.7% | 17.4% | 36.5 | -21.8% |
| UPB Upstream Bio |
Biotechnology
Verekitug, Asthma, Rhinosinusitis |
1.09B | 34.2% | - | -23.6% | - | -18.4% |
| NUVB Nuvation Bio |
Biotechnology
Oncology Pipeline Drug Candidates |
1.08B | 29.9% | - | 13.0% | - | -10.4% |
| ATNF 180 Life Sciences |
Biotechnology
Anti Tnf Therapy, Fibrosis |
1.08B | 46.0% | - | -54.2% | - | -3.34% |
| ZYME Zymeworks Common |
Biotechnology
Bispecific Antibodies |
1.07B | 30.7% | - | 41.5% | - | 8.85% |
| MDXG MiMedx |
Biotechnology
Allograft, Wound, Graft, Membrane |
1.05B | 79.4% | - | 42.3% | 33.9 | -4.79% |
| SPRY ARS |
Biotechnology
Cancer Antibody,Immune |
1.02B | 41.2% | - | 22.7% | - | -38.1% |
| ORIC Oric |
Biotechnology
Androgen, Kinase, Precision |
1.02B | 29.0% | - | 27.3% | - | -12.1% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Intranasal, Oral |
1.01B | 33.2% | - | 34.0% | - | 204% |
| PHARM Pharming |
Biotechnology
RUCONEST, Joenja, OTL-105 |
992M | 49.6% | - | 37.3% | - | 42.2% |
| GERN Geron |
Biotechnology
telomerase, inhibitor, oncology |
938M | 36.2% | - | -61.6% | - | -76.5% |
| ZBIO Zenas BioPharma |
Biotechnology
Monoclonal Antibody |
906M | 28.4% | - | 9.11% | - | -8.77% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia Treatment |
904M | 38.3% | - | 1.21% | - | 113% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
896M | 34.1% | - | 40.4% | - | 18.9% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal, Antibodies |
895M | 25.7% | - | -36.4% | - | -55.5% |
| TSHA Taysha Gene |
Biotechnology
Gene, Therapy, AAV, CNS, Monogenic |
884M | 28.0% | - | 21.0% | - | 12.2% |
| AVXL Anavex Life |
Biotechnology
Cns,Alzheimer,Parkinson,Rett,Epilep.. |
881M | 30.1% | - | 15.9% | - | 35.7% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
870M | 28.0% | - | 28.4% | - | 30.2% |
| AKBA Akebia Ther |
Biotechnology
Anemia,Hyperphosphatemia,Iron-Defic.. |
827M | 27.1% | - | 72.1% | - | 72.4% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
819M | 35.0% | - | -29.7% | - | -38.3% |
| TNGX Tango Therapeutics |
Biotechnology
Precision, cancer, treatments |
818M | 23.2% | - | 10.7% | - | -25.4% |
| IMNM Immunome |
Biotechnology
Antibody, Oncology, Bispecific |
808M | 29.2% | - | -2.92% | - | -50.8% |
| IOVA Iovance |
Biotechnology
Amtagvi, Proleukin, Lifileucel |
800M | 37.8% | - | -88.6% | - | -82.0% |
| PRAX Praxis Precision |
Biotechnology
Cns Therapies, Epilepsy Treatments |
794M | 23.6% | - | -33.9% | - | -35.6% |
| VLA Valneva SE |
Biotechnology
Vaccine, Japanese Encephalitis |
789M | 27.1% | - | -7.03% | - | 33.2% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, DNTH103 |
781M | 23.3% | - | 1.74% | - | 26.2% |
| IVA Inventiva |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
780M | 39.5% | - | 31.6% | - | 104% |
| SION Sionna |
Biotechnology
CFTR,Cystic,COPD,Lungs,Genes |
769M | 22.6% | - | 66.7% | - | 12.9% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
761M | 40.5% | - | 5.06% | - | 79.2% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Pain |
760M | 61.8% | - | 55.9% | - | 5.66% |
| SANA Sana Biotechnology |
Biotechnology
Engineered Cells, Cell Therapies |
752M | 40.6% | - | -52.7% | - | -40.4% |
| VALN Valneva SE |
Biotechnology
Japanese Encephalitis Vaccine |
740M | 14.6% | - | 1.27% | - | 38.6% |
| CDNA CareDx |
Biotechnology
Kidney, Heart, Transplant |
737M | 48.0% | - | -55.2% | 13.2 | -59.9% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
732M | 24.5% | - | 28.0% | - | -8.39% |
| KURA Kura Oncology |
Biotechnology
Ziftomenib, Tipifarnib, KO-2806 |
732M | 42.2% | - | -64.5% | - | -66.1% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
728M | 27.6% | - | -81.7% | - | -57.1% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002, Pulmonary |
728M | 35.9% | - | -12.9% | - | 181% |
| NRIX Nurix Therapeutics |
Biotechnology
Cancer, Autoimmune, Inflammatory |
723M | 32.1% | - | -67.7% | - | -70.9% |
| RIGL Rigel |
Biotechnology
Tavalisse, Rezlidhia, GAVRETO |
720M | 91.9% | - | 49.4% | 7.30 | 111% |
| MNMD Mind Medicine |
Biotechnology
Phase 3 Anxiety, Phase 1 Autism |
718M | 20.1% | - | 32.7% | - | 33.2% |
| VIR Vir Biotechnology |
Biotechnology
Hepatitis, Influenza, Coronavirus |
713M | 27.1% | - | -83.6% | - | -48.9% |
| RLAY Relay Therapeutics |
Biotechnology
Precision, Oncology, Genetics |
709M | 29.6% | - | -84.1% | - | -54.6% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitors, Oral |
708M | 35.4% | - | 17.4% | - | 6.80% |
| IMTX Immatics |
Biotechnology
ACT, Bispecifics, T-Cell |
706M | 31.9% | - | -54.9% | - | -58.2% |
| GYRE Gyre Therapeutics |
Biotechnology
Anti-Fibrotic, Anti-Inflammatory |
698M | 58.5% | 1.0% | -11.2% | 385 | -54.7% |
| MYGN Myriad Genetics |
Biotechnology
Cancer Tests, Genetic Tests |
698M | 39.7% | 0.08% | -81.5% | - | -78.2% |
| TRML Tourmaline Bio |
Biotechnology
Monoclonal Antibody, Medicines |
687M | 27.4% | 1.0% | 28.2% | - | 108% |
| SECARE Swedencare publ |
Biotechnology
Supplements, Treats, Grooming |
680M | 52.2% | 57.8% | -36.0% | 96.6 | -24.9% |
| DNA Ginkgo Bioworks |
Biotechnology
Cell Engineering, Biosecurity |
671M | 18.2% | - | -36.5% | - | 37.1% |
| RZLT Rezolute |
Biotechnology
Monoclonal Antibody, Oral |
669M | 28.0% | - | 32.8% | - | 30.4% |
| SVRA Savara |
Biotechnology
Biopharmaceutical, Granulocyte |
660M | 22.5% | - | 26.0% | - | -31.4% |
| KROS Keros Therapeutics |
Biotechnology
Blood, Heart, Muscle, Cell |
638M | 63.1% | - | -63.2% | 49.1 | -76.1% |
| TYRA Tyra Biosciences |
Biotechnology
TYRA-300, TYRA-200, TYRA-430 |
635M | 23.9% | - | -2.53% | - | -54.2% |
| BCAX Bicara |
Biotechnology
Bifunctional, Therapies, Solid |
634M | 18.7% | - | -88.8% | - | -65.8% |
| ANAB AnaptysBio |
Biotechnology
Antibodies, Modulators |
630M | 40.6% | - | -28.3% | - | -55.4% |
| ORGO Organogenesis |
Biotechnology
Wound Grafts, Skin Substitutes |
629M | 29.7% | - | 32.3% | - | 33.9% |
| CSTL Castle Biosciences |
Biotechnology
Dermatologic, Cancer, Diagnostics |
621M | 59.6% | - | -56.0% | - | -41.1% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene, Therapy, Ocular |
603M | 39.4% | - | 10.5% | - | 44.8% |
| PRME Prime Medicine |
Biotechnology
Gene Editing Technology, Prime |
595M | 39.0% | - | -44.4% | - | -1.92% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Cancer |
594M | 26.4% | - | -87.8% | - | -62.9% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal, Antibodies, Psoriasis |
592M | 19.8% | 1.0% | -26.4% | - | -48.3% |
| CMPX Compass |
Biotechnology
Antibody, Therapeutics |
590M | 23.5% | - | 33.1% | - | 78.4% |
| VSTM Verastem |
Biotechnology
Cancer Drugs, Tumor Inhibitors |
585M | 37.7% | - | 2.87% | - | 186% |
| ESPR Esperion |
Biotechnology
Cholesterol Lowering Medication |
561M | 48.4% | - | -46.6% | - | 28.9% |
| ATYR aTyr Pharma |
Biotechnology
Therapeutic Candidates, Fibrosis |
536M | 24.5% | - | -29.5% | - | -53.0% |
| OLMA Olema |
Biotechnology
Estrogen Receptor Antagonist |
520M | 28.0% | - | -2.35% | - | -46.7% |
| KOD Kodiak Sciences |
Biotechnology
Therapeutic Antibodies, Biopolymer |
517M | 41.5% | - | 5.22% | - | 190% |
| RGNX Regenxbio |
Biotechnology
Gene Therapy, Biotechnology, NAV |
498M | 30.2% | - | -66.3% | - | -41.2% |